Peter Riedell, MD, University of Chicago Medicine, Chicago, IL, comments on the key topics of a talk designed to provide oncologists and bone marrow transplant (BMT) specialists with an overview of CAR-T therapy in diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). The presentation recapitulated data on the three approved CAR-T products in DLBCL in the third-line setting, axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel), as well as data from the three pivotal trials comparing these CAR-T therapies to standard of care (SOC) in second line in DLBCL. Advances in MCL were also highlighted and included data showing the benefits of brexucabtagene autoleucel (brexu-cel) in these patients. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.